At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 165 enrolled
Drug / intervention
TBE vaccine 0.5 mL +1 morebiological
Likely dose
TBE vaccine 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A TICK-BORNE ENCEPHALITIS VACCINE IN HEALTHY JAPANESE PARTICIPANTS 1 YEAR OF AGE AND OLDER
In Brief
A Phase 3 clinical trial evaluating TBE vaccine 0.5 mL and TBE vaccine 0.25 mL for Tick-Borne Encephalitis. Completed, enrolled 165 participants across 6 sites.
Detailed Summary
The main purpose of this study is to provide safety and immunogenicity data in Japanese participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTick-Borne Encephalitis
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartJan 2021
Primary CompletionFeb 2022
TodayJul 2026
First PostedDec 1, 2020
Enrollment StartJan 18, 2021
Primary CompletionFeb 21, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.6 years ago
Interventions
TBE vaccine 0.5 mLbiological
TBE vaccine 0.5 mL (intramuscular injection).
TBE vaccine 0.25 mLbiological
TBE vaccine 0.25 mL (intramuscular injection).